TY - JOUR
T1 - Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease
AU - Olson, Katherine E.
AU - Gendelman, Howard E.
N1 - Funding Information:
This work was supported, in part, by the University of Nebraska Foundation which includes individual donations from Carol Swarts and Frances and Louie Blumkin, the Vice Chancellor's office of the University of Nebraska Medical Center for Core Facility Developments and National Institutes of Health grants P01 DA028555 , R01 NS36126 , P01 NS31492 , 2R01 NS034239 , P01 MH64570 , P01 NS43985 , P30 MH062261 and R01 AG043540 . Our research is also supported by the Department of Defense grant W81XWH11-1-0700 .
Publisher Copyright:
© 2015 Elsevier Ltd. All rights reserved.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - While immune control is associated with nigrostriatal neuroprotection for Parkinson's disease, direct cause and effect relationships have not yet been realized, and modulating the immune system for therapeutic gain has been openly debated. Here, we review how innate and adaptive immunity affect disease pathobiology, and how each could be harnessed for treatment. The overarching idea is to employ immunopharmacologics as neuroprotective strategies for disease. The aim of the current work is to review disease-modifying treatments that are currently being developed as neuroprotective strategies for PD in experimental animal models and for human disease translation. The long-term goal of this research is to effectively harness the immune system to slow or prevent PD pathobiology.
AB - While immune control is associated with nigrostriatal neuroprotection for Parkinson's disease, direct cause and effect relationships have not yet been realized, and modulating the immune system for therapeutic gain has been openly debated. Here, we review how innate and adaptive immunity affect disease pathobiology, and how each could be harnessed for treatment. The overarching idea is to employ immunopharmacologics as neuroprotective strategies for disease. The aim of the current work is to review disease-modifying treatments that are currently being developed as neuroprotective strategies for PD in experimental animal models and for human disease translation. The long-term goal of this research is to effectively harness the immune system to slow or prevent PD pathobiology.
UR - http://www.scopus.com/inward/record.url?scp=84946606692&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946606692&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2015.10.006
DO - 10.1016/j.coph.2015.10.006
M3 - Review article
C2 - 26571205
AN - SCOPUS:84946606692
VL - 26
SP - 87
EP - 95
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
SN - 1471-4892
ER -